Navigation Links
Double duty: Loss of protective heart failure protein causes high blood pressure
Date:5/5/2008

(PHILADELPHIA) Scientists at the Center for Translational Medicine at Thomas Jefferson University in Philadelphia have found that a protein that appears to have protective and perhaps healing effects for failing hearts also plays a similar role in high blood pressure. They found lower-than-normal levels of the protein S100A1 in cells that line blood vessel walls in animals with high blood pressure.

When the researchers, led by Patrick Most, M.D., assistant professor of Medicine at Jefferson Medical College and former postdoctoral fellow Sven Pleger, M.D., experimentally lowered the amount of S100A1 protein in the animals blood vessels, they were able to dramatically increase blood pressure. The preliminary results identified a novel and rather unanticipated biological function of the protein and suggest that S100A1 could be a therapeutic target for blood pressure treatment. The teams findings appear in the journal Circulation Research.

S100A1 seems to be a major player in the regulation of blood pressure and vascular function, says Dr. Most. The mechanisms by which this works is by producing more nitric oxide (NO) in the endothelial cells that line the vessel walls. A lack of NO enables hypertension.

According to Dr. Most, S100A1 is an alternative mechanism for increasing heart function. It directly regulates calcium circulation, which drives the contractions in the heart. Dr. Mosts laboratory has been working on S100A1s role in disease hearts for more than a decade, and together with a group led by Walter Koch, Ph.D, director of the Center for Translational Medicine, they have proven that loss of the protein causes diseased hearts to fail and that the protein is a potential target for gene therapy for heart failure.

S100A1, part of a larger family of proteins called S100, is primarily found at high levels in muscle, particularly the heart. Falling levels of S100A1 are critical in the loss of heart-pumping strength after a heart attack and play an important role in the progression to heart failure. A previous study in 1989 showed that the protein was reduced by as much as 50 percent in patients with heart failure.

In the current work, Dr. Most and colleague Andrea Eckhart, Ph.D., associate professor of Medicine at Jefferson Medical College, and their team found in both laboratory experiments and in animal models that blood vessels that lack S100A1 cannot relax as well as normal vessels. If the animal doesnt have S100A1, it has hypertension, he says. The mechanism is based more or less on the availability of nitric oxide. It seems that S100A1 also regulates calcium cycling in the endothelial cell, and calcium is needed in the endothelial cell to stimulate NO production. The loss of S100A1 impairs the calcium mobilization of the endothelial cell thats the link between less calcium, less NO, hypertension and endothelial dysfunction.

As a result, Dr. Most says, S100A1 might not only be a good therapeutic target for heart failure, but for hypertension as well. Current projections estimate that 29.2 percent of the adult population worldwide about 1.56 billion people will have hypertension by 2025. Hypertension has long been the most common risk factor for the development of congestive heart failure, affecting nearly five million Americans, many of whom have poor long-term prognoses, despite recent therapeutic advances.

The researchers plan to continue to investigate animal models of hypertension, noting that the current work was only possible because of the collaborative efforts of those in the Center for Translational Medicine and also the Department of Physiology. If the scientists find a lack of S100A1 in blood vessels, then they will develop treatments using the Centers in-house capabilities to generate viral delivery that can be tailored to express genes in endothelial cells. We will test genetically engineered animals to find out whether or not replacing S100A1 can decrease blood pressure, he notes.

In addition, the researchers will test a recently developed approach employing only a small fragment of the protein with a similar therapeutic potency. This fragment, Dr. Most explains, is 10 times smaller than the protein and allows a direct application in the bloodstream, almost like a real drug. The researchers hope that either the small protein fragment itself or a synthetic analogue will enable a novel therapeutic approach to treat both heart failure and hypertensive patients in the near future.


'/>"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Pre-Pregnancy Diabetes Rates Have Doubled
2. Todays Working Adults Face Long Term Care Double Whammy, Says Denise Gott, Spokesperson for LTC Financial Partners, LLC
3. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
4. Combining liver cancer treatments doubles survival rates, UVA researchers find
5. Los Angeles Ronald McDonald House Doubles Lodging Capacity for Families of Hospitalized Children
6. Double binding sites on tumor target may provide future combination therapy
7. Gum Disease, HPV a Double Whammy
8. Uroplasty Plans to Double Sales Force During Fiscal 2009
9. Diabetics Face Doubled Risk of Heart Attack
10. Ford Launches Warriors in Pink Mustang for 09, Doubles Contributions To Race For The Cure
11. Diversified Clinical Services Doubles Field Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... Phytocéane ... Indian Ocean, isolated from the rest of the world with ZANZIBAR SHOWER GEL. Inspired ... Phytocéane used key ingredients, Virgin Coconut Oil and moisturizing vegetal coral to create this ...
(Date:1/21/2017)... ... January 21, 2017 , ... The ... Dr. Dan Holtzclaw in media for its creos™ line of bone regenerative products. ... Dr. Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for a variety ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company ... January ECRM trade show to continue the marketing and distribution of its product, The ... for providing 400 percent better absorption than traditional vitamin C supplements. At the trade ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser ... Cancer Institute. For Betsy, the clinical trial has been life-saving as she has ... worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent ...
(Date:1/20/2017)... ... ... Word: Chocolate Biscuit”: a biographical account following a man who went on to support his ... Marlyn Ivey, born in Lynn Haven, Florida and at the age of 5, his family ... age, he joined the Navy and got married right out of boot camp. , ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Germany Cataract Surgery Devices Market Outlook ... Cataract Surgery Devices Market Outlook to 2022", provides key ... The report provides value, in millions of US dollars, ... segements - Phacoemulsification Equipment and Ophthalmic Viscoelastic Devices (OVD). ... shares data for each of these market segements, and ...
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Which areas are going to grow at the fastest ... 2026, assessing data, trends, opportunities and prospects. Our ... the most lucrative areas in the industry and the ... forecasted sales across the all the major categories of ...
(Date:1/19/2017)... , Jan. 19, 2017 The U.S. Food ... of Chronic Idiopathic Constipation (CIC) in adult patients. ... chronic gastrointestinal disorders," said Julie Beitz , M.D., director ... Center for Drug Evaluation and Research. "With the availability of ... appropriate treatment for their condition." ...
Breaking Medicine Technology: